4-fluoro-3-(5-isopropyl-[1,2,4]triazol-1-yl)-N-(5-methyl-pyrazin-2-ylmethyl)-5-(5-methyl-pyridin-2-yl)-benzamide | 1161872-45-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: 4-fluoro-3-(5-isopropyl-[1,2,4]triazol-1-yl)-N-(5-methyl-pyrazin-2-ylmethyl)-5-(5-methyl-pyridin-2-yl)-benzamide
• 英文别名: 4-fluoro-N-[(5-methylpyrazin-2-yl)methyl]-3-(5-methylpyridin-2-yl)-5-(5-propan-2-yl-1,2,4-triazol-1-yl)benzamide
• CAS: 1161872-45-2
• 化学式: C₂₄H₂₄FN₇O
• 分子量: 445.499
• InChiKey: YPECDPRAXMVJPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  98.5
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists
  申请人：Chen Li

  公开号：US20090170874A1

  公开（公告）日：2009-07-02

  Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R 1 is optionally substituted triazolyl, and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X 3 and/or a P2X 2/3 receptor antagonists and methods of making the compounds.

  公式I的化合物：或其药用盐，其中，R1是可选择地取代的三唑基，R2、R3、R4、R5、R6、R7和R8如本文所定义。还公开了使用这些化合物治疗与P2X3和/或P2X2/3受体拮抗剂相关的疾病的方法，以及制备这些化合物的方法。
• TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS
  申请人：Chen Li

  公开号：US20110245271A1

  公开（公告）日：2011-10-06

  Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R 1 is optionally substituted triazolyl, and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X 3 and/or a P2X 2/3 receptor antagonists and methods of making the compounds.

  公式I的化合物或其药学上可接受的盐，其中R1是可选取代的三唑基，而R2、R3、R4、R5、R6、R7和R8如本文所定义。还公开了使用这些化合物治疗与P2X3和/或P2X2/3受体拮抗剂相关的疾病的方法以及制备这些化合物的方法。
• TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS
  申请人：Roche Palo Alto LLC

  公开号：US20150065521A1

  公开（公告）日：2015-03-05

  Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R 1 is optionally substituted triazolyl, and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X 3 and/or a P2X 2/3 receptor antagonists and methods of making the compounds.

  化合物I的公式为：或其药学上可接受的盐，其中，R1是可选取代的三唑基，而R2、R3、R4、R5、R6、R7和R8的定义如本文所述。还公开了使用这些化合物治疗与P2X3和/或P2X2/3受体拮抗剂相关的疾病的方法以及制备这些化合物的方法。
• Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2607356A1

  公开（公告）日：2013-06-26

  Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted triazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

  式 I 的化合物： 或其药学上可接受的盐，其中，R1 是任选取代的三唑基，R2、R3、R4、R5、R6、R7 和 R8 如本文所定义。还公开了使用这些化合物治疗与P2X3和/或P2X2/3受体拮抗剂相关疾病的方法以及制造这些化合物的方法。
• TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2225213B1

  公开（公告）日：2015-04-29